射频消融治疗肝细胞癌的预后因素及研究新进展

Radiofrequency ablation of hepatocellular carcinoma:Prognostic factors and recent advances

随着医学诊疗水平的提高,射频消融在治疗原发性肝癌的临床应用和基础研究方面都取得飞速进展,发挥着越来越重要的作用:(1)射频消融治疗原发性肝癌的10年总生存率为27.3%-46.1%,对于肿瘤单发且最大径≤3 cm的HCC患者,10年总生存率可达74%,生存结果与手术切除相似;(2)射频消融联合其他治疗等可以扩大消融治疗的适应证,使患者生存获益;(3)建立预测射频消融治疗原发性肝癌的预后模型,可指导制定治疗和随访策略,为临床个体化诊疗提供重要依据.

With the improvement of technology and diagnostic level,radiofrequency ablation(RFA)has made rapid progress in the treatment of primary hepatocellular carcinoma(HCC)in the past two decades.Especially,the overall survival after the treatment of small HCCs by RFA can be comparable to that achieved by hepatic resection.The 10-year survival rates of RFA for HCC were 27.3%-46.1%,and for solitary HCC less than 3 cm,the 10-year survival rate is about 74.0%.RFA combined with other therapies can expand the indications of RFA treatment and benefit the survival of patients with HCC.The prognostic model of RFA for HCC provides a powerful tool for individualized clinical diagnosis and treatment.